Mega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s long-term effects; Biogen’s ALS flop; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

In a few weeks, I’ll be fly­ing out to San Diego for the an­nu­al BIO con­fer­ence, where End­points News will host a par­al­lel event to ex­plore some of the most im­por­tant is­sues dri­ving the bio­phar­ma in­dus­try. Check out the full agen­da here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.